Tags

Type your tag names separated by a space and hit enter

Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial.
Br J Nutr 2012; 107(11):1682-93BJ

Abstract

Depressive symptoms may increase the risk of progressing from mild cognitive impairment (MCI) to dementia. Consumption of n-3 PUFA may alleviate both cognitive decline and depression. The aim of the present study was to investigate the benefits of supplementing a diet with n-3 PUFA, DHA and EPA, for depressive symptoms, quality of life (QOL) and cognition in elderly people with MCI. We conducted a 6-month double-blind, randomised controlled trial. A total of fifty people aged >65 years with MCI were allocated to receive a supplement rich in EPA (1·67 g EPA + 0·16 g DHA/d; n 17), DHA (1·55 g DHA + 0·40 g EPA/d; n 18) or the n-6 PUFA linoleic acid (LA; 2·2 g/d; n 15). Treatment allocation was by minimisation based on age, sex and depressive symptoms (Geriatric Depression Scale, GDS). Physiological and cognitive assessments, questionnaires and fatty acid composition of erythrocytes were obtained at baseline and 6 months (completers: n 40; EPA n 13, DHA n 16, LA n 11). Compared with the LA group, GDS scores improved in the EPA (P=0·04) and DHA (P=0·01) groups and verbal fluency (Initial Letter Fluency) in the DHA group (P=0·04). Improved GDS scores were correlated with increased DHA plus EPA (r 0·39, P=0·02). Improved self-reported physical health was associated with increased DHA. There were no treatment effects on other cognitive or QOL parameters. Increased intakes of DHA and EPA benefited mental health in older people with MCI. Increasing n-3 PUFA intakes may reduce depressive symptoms and the risk of progressing to dementia. This needs to be investigated in larger, depressed samples with MCI.

Authors+Show Affiliations

School of Health Sciences, Sansom Institute for Health Research, Nutritional Physiology Research Centre, University of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia. natalie.sinn@unisa.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21929835

Citation

Sinn, Natalie, et al. "Effects of N-3 Fatty Acids, EPA V. DHA, On Depressive Symptoms, Quality of Life, Memory and Executive Function in Older Adults With Mild Cognitive Impairment: a 6-month Randomised Controlled Trial." The British Journal of Nutrition, vol. 107, no. 11, 2012, pp. 1682-93.
Sinn N, Milte CM, Street SJ, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr. 2012;107(11):1682-93.
Sinn, N., Milte, C. M., Street, S. J., Buckley, J. D., Coates, A. M., Petkov, J., & Howe, P. R. (2012). Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. The British Journal of Nutrition, 107(11), pp. 1682-93. doi:10.1017/S0007114511004788.
Sinn N, et al. Effects of N-3 Fatty Acids, EPA V. DHA, On Depressive Symptoms, Quality of Life, Memory and Executive Function in Older Adults With Mild Cognitive Impairment: a 6-month Randomised Controlled Trial. Br J Nutr. 2012;107(11):1682-93. PubMed PMID: 21929835.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. AU - Sinn,Natalie, AU - Milte,Catherine M, AU - Street,Steven J, AU - Buckley,Jonathan D, AU - Coates,Alison M, AU - Petkov,John, AU - Howe,Peter R C, Y1 - 2011/09/20/ PY - 2011/9/21/entrez PY - 2011/9/21/pubmed PY - 2012/8/15/medline SP - 1682 EP - 93 JF - The British journal of nutrition JO - Br. J. Nutr. VL - 107 IS - 11 N2 - Depressive symptoms may increase the risk of progressing from mild cognitive impairment (MCI) to dementia. Consumption of n-3 PUFA may alleviate both cognitive decline and depression. The aim of the present study was to investigate the benefits of supplementing a diet with n-3 PUFA, DHA and EPA, for depressive symptoms, quality of life (QOL) and cognition in elderly people with MCI. We conducted a 6-month double-blind, randomised controlled trial. A total of fifty people aged >65 years with MCI were allocated to receive a supplement rich in EPA (1·67 g EPA + 0·16 g DHA/d; n 17), DHA (1·55 g DHA + 0·40 g EPA/d; n 18) or the n-6 PUFA linoleic acid (LA; 2·2 g/d; n 15). Treatment allocation was by minimisation based on age, sex and depressive symptoms (Geriatric Depression Scale, GDS). Physiological and cognitive assessments, questionnaires and fatty acid composition of erythrocytes were obtained at baseline and 6 months (completers: n 40; EPA n 13, DHA n 16, LA n 11). Compared with the LA group, GDS scores improved in the EPA (P=0·04) and DHA (P=0·01) groups and verbal fluency (Initial Letter Fluency) in the DHA group (P=0·04). Improved GDS scores were correlated with increased DHA plus EPA (r 0·39, P=0·02). Improved self-reported physical health was associated with increased DHA. There were no treatment effects on other cognitive or QOL parameters. Increased intakes of DHA and EPA benefited mental health in older people with MCI. Increasing n-3 PUFA intakes may reduce depressive symptoms and the risk of progressing to dementia. This needs to be investigated in larger, depressed samples with MCI. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/21929835/Effects_of_n_3_fatty_acids_EPA_v__DHA_on_depressive_symptoms_quality_of_life_memory_and_executive_function_in_older_adults_with_mild_cognitive_impairment:_a_6_month_randomised_controlled_trial_ L2 - https://www.cambridge.org/core/product/identifier/S0007114511004788/type/journal_article DB - PRIME DP - Unbound Medicine ER -